It is a very good question, and I think it's a question on Canadians' minds right now.
I've already spoken about the importance of the regulatory approval process, and I want to to set out the stages that we are working on in the logistics process. After regulatory approval, we need to also think about biomanufacturing and fill-and-finish capacity here in Canada, because some vaccines may arrive in vat format that will require filling and finishing to occur here in Canada. Once that occurs—and we're hoping that we will have a Canadian facility here to do that to some extent in the Royalmount facility in Quebec that I mentioned—there's the distribution process.
As for your attention to the need for storage or refrigeration at -75°C for the Pfizer vaccine, that is part of the distribution process. We have put in place contracts for deep freeze and refrigeration to enable us to meet the needs of the vaccines made by Pfizer and Moderna. For example, we will have the ability to store 33.5 million doses at a time in the freezers for ultra-frozen and frozen vaccine storage that we just put in place last week.
In addition to the distribution of vaccines, we are also working on supporting the provinces and territories in the administration of the vaccines. In that regard, we have procured 90 million syringes, 100 million needles, Sharps containers, 90 million alcohol swabs, 75 million bandages and gauze strips. This is very much a collaborative approach with the provinces and territories. We are placing orders based on indications and orders that are coming from the Public Health Agency of Canada. It is not just PSPC deciding what should be ordered. Based on the vaccine task force and the Public Health Agency of Canada, we are putting in place the logistics and the distribution systems.